Actionnariat et activité des initiés pour Lineage Cell Therapeutics, Inc. (LCTX): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $1.07 |
| Capitalisation | $267M |
| Bourse | AMEX |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $22.1M | $36.8M | $23.6M | $9.5M | $32.6M | $55.7M | $11.4M | $35.4M | $45.8M | $40.8M |
| Placements à Court Terme | $627000 | $1.3M | $7.2M | $21.2M | $9.0M | $2.6M | $46.5M | $50000 | $2.0M | $15.0M |
| Créances | $1.2M | $3.0M | $3.7M | $24.7M | $4000 | $51.1M | $297000 | $745000 | $638000 | $1.6M |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $25.6M | $42.6M | $36.4M | $57.5M | $44.0M | $111.5M | $60.0M | $38.4M | $51.0M | $59.2M |
| Immobilisations Corporelles | $5.5M | $5.5M | $5.8M | $8.2M | $5.6M | $4.9M | $5.7M | $4.8M | $4.4M | $4.7M |
| Goodwill | 0 | 0 | 0 | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M | $10.7M |
| Actifs Incorporels | $10.2M | $6.9M | $3.1M | $48.2M | $47.0M | $46.8M | $46.7M | $46.6M | $46.5M | $31.7M |
| Actifs Totaux | $142.6M | $173.2M | $101.7M | $125.5M | $107.9M | $174.5M | $123.7M | $101.0M | $113.2M | $112.6M |
| Dettes Fournisseurs | $1.6M | $938000 | $2.4M | $2.4M | $2.6M | $3.5M | $2.4M | $2.0M | $1.2M | $2.3M |
| Dette à Court Terme | $932000 | $152000 | $70000 | $1.2M | $523000 | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $8.8M | $6.9M | $6.8M | $6.5M | $7.8M | $47.1M | $19.0M | $18.0M | $14.0M | $11.4M |
| Dette à Long Terme | $1.2M | $18000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Totaux | $12.1M | $9.0M | $9.4M | $14.2M | $12.8M | $83.6M | $51.7M | $39.0M | $36.2M | $69.2M |
| Réserves | -$196.3M | -$216.3M | -$261.9M | -$273.4M | -$294.1M | -$337.1M | -$363.4M | -$384.9M | -$403.5M | -$467.0M |
| Capitaux Propres | $117.9M | $162.6M | $93.8M | $113.0M | $96.2M | $92.2M | $73.3M | $63.4M | $78.4M | $44.5M |
| Dette Totale | $4.0M | $1.5M | $2.3M | $5.2M | $3.8M | $2.8M | $3.9M | $3.0M | $2.5M | $2.4M |
| Dette Nette | -$18.7M | -$36.6M | -$28.5M | -$25.5M | -$37.7M | -$55.6M | -$54.0M | -$32.5M | -$45.3M | -$53.4M |
| Fonds de Roulement | $16.8M | $35.7M | $29.5M | $51.0M | $36.2M | $64.4M | $41.0M | $20.5M | $37.0M | $47.8M |
Santé financière
| Dette / Capitaux propres | 0.04 |
| Ratio de liquidité | 6.61 |
Rentabilité
| Rentabilité des capitaux propres | -71.14% |
| Rentabilité du capital investi | -23.25% |
| Rentabilité des actifs | -30.37% |
| Marge brute | 96.59% |
| Marge opérationnelle | -205.23% |
| Marge nette | -246.58% |
Entreprises liées: ADCT · AUTL · BNTC · FULC · GALT · NGNE · OCGN
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de LCTX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions